Workers compensation prescription costs are rising again. Quarterly prescription payments per medical claim climbed 24% between Q1 2022 and Q1 2025, from $51 to $63, across 31 study states, according to the Workers Compensation Research Institute’s 2026 Prescription Drug Regulations National Inventory, released February 25, 2026. The reversal erases more than a decade of declining WC pharmaceutical costs that followed opioid reform.
The driver is not opioids returning. Opioids represented just 3% of prescription payments in the median state in Q1 2025, with per-claim payments falling in nearly every state. The pressure is coming from non-opioid specialty categories. Dermatological agents, primarily topical analgesics, held 23% of payments in the median state and exceeded 30% in 12 states, reaching 56% in Pennsylvania. Migraine biologics, including brand CGRP inhibitors (calcitonin gene-related peptide inhibitors) priced between $970 and $2,000 per month, are growing fastest, per Enlyte’s 2026 Drug Utilization Report, which also documented a 5.5% drop in opioid utilization alongside the specialty cost surge.
Who It Affects
The programs most exposed are self-insured employers in sectors with high soft-tissue and musculoskeletal injury rates: manufacturing, warehousing, construction, healthcare systems, and public safety. Captive programs and group pools carry the same exposure; the pharmaceutical cost shift is not confined to any single injury type or sector.
State context matters considerably. Quarterly prescription payments per claim ranged from roughly $14 in Minnesota to $353 in Louisiana in Q1 2025, a 25-fold difference. Self-insured programs with significant exposure in Louisiana, Texas, Pennsylvania, and New York, states without binding WC drug formularies or fee schedule ceilings on specialty agents, face the fastest-moving gap between historical development factors and current claim behavior. The concurrent state regulatory responses to topical compound cost growth show both how fast specialty drug costs can move and how unevenly states have acted.
The Reserve Mechanism
The actuarial problem is embedded in the development triangles. Most self-insured WC programs built their current loss development factors from 2016 through 2021 accident years, a period when WC drug costs declined 3 to 5% annually. Every age-to-age factor above year one reflects that favorable pharmaceutical trend: actual paid medical development ran below expected, and the resulting factors carry an implicit negative drug cost assumption.
Since 2022, that assumption has reversed. Development factors built on the declining-cost era now understate emerging medical payments in years four through seven, when chronic injury conditions generate ongoing pharmacy spend for pain management, anti-inflammatory agents, and specialty biologics. A workers compensation IBNR review that applies 2018-2021 development patterns to current claims is projecting a pharmaceutical cost environment that no longer exists.
The effect compounds quietly. A program whose overall medical loss ratio appears stable may not detect the drag until a formal reserve review compares actual paid medical against expected and finds a systematic shortfall in the pharmacy component. Georgia offers the clearest evidence of the mechanism: an April 2024 state fee schedule cap on topical medications reduced dermatological payment shares from 55% to 17% by Q1 2025, confirming that specialty drug costs are regulation-sensitive and that states without comparable controls carry structurally higher development risk. Drug cost reversals of this type qualify as one of the five leading indicators of adverse reserve development.
What This Means for Your Next Review
Put two questions to your actuary before the next reserve study. First: what pharmaceutical cost trend is embedded in the medical severity development factors, and does it reflect post-2022 data or the pre-2022 declining period? Second: has the medical development triangle been segmented to isolate pharmacy spend from hospital, surgery, and rehabilitation, so the drug cost reversal shows up distinctly rather than blending into a general medical trend?
If your program has open claims involving ongoing specialty prescriptions, including topical analgesics, migraine biologics, or anti-inflammatory agents past year three of development, those claims are entering the window where the old favorable trend assumption is most likely to produce reserve shortfalls.
Sources
- WCRI, Workers’ Compensation Prescription Drug Regulations: A National Inventory, 2026: https://www.wcrinet.org/reports/workers-compensation-prescription-drug-regulations-a-national-inventory-2026
- Enlyte, 2026 Drug Utilization Report: https://www.enlyte.com/drug-trends
- Risk and Insurance, WC Drug Costs Reverse Course, Rising Sharply Across Most States: https://riskandinsurance.com/workers-comp-drug-costs-reverse-course-rising-sharply-across-most-states/
- Risk and Insurance, Opioid Use Drops While Specialty Drug Costs Surge in Workers Compensation: https://riskandinsurance.com/opioid-use-drops-while-specialty-drug-costs-surge-in-workers-compensation/